Deepak Ravindranathan
A5060651878- Cancer Immunotherapy and Biomarkers
- Bladder and Urothelial Cancer Treatments
- COVID-19 and healthcare impacts
- Crystallization and Solubility Studies
- X-ray Diffraction in Crystallography
- Prostate Cancer Treatment and Research
- Inflammatory Biomarkers in Disease Prognosis
- COVID-19 Clinical Research Studies
- Renal cell carcinoma treatment
- Cancer Genomics and Diagnostics
- Urinary and Genital Oncology Studies
- Catalytic C–H Functionalization Methods
- Organometallic Complex Synthesis and Catalysis
- Prostate Cancer Diagnosis and Treatment
- Economic and Financial Impacts of Cancer
- Global Cancer Incidence and Screening
- Multiple and Secondary Primary Cancers
- Healthcare cost, quality, practices
- Glioma Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Lanthanide and Transition Metal Complexes
- Cancer, Hypoxia, and Metabolism
- Cancer, Lipids, and Metabolism
- Catalytic Alkyne Reactions
- Catalytic Cross-Coupling Reactions
Emory University
2017-2024
Grady Memorial Hospital
2022
East Carolina University
2010-2015
Patients with cancer may be at high risk of adverse outcomes from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. We analyzed a cohort patients and 2019 (COVID-19) reported to the COVID-19 Cancer Consortium (CCC19) identify prognostic clinical factors, including laboratory measurements anticancer therapies. active or historical laboratory-confirmed SARS-CoV-2 diagnosis recorded between 17 March 18 November 2020 were included. The primary outcome was severity measured...
<h3>Importance</h3> Non-Hispanic Black individuals experience a higher burden of COVID-19 than the general population; hence, there is an urgent need to characterize unique clinical course and outcomes in patients with cancer. <h3>Objective</h3> To investigate racial disparities severity presentation, complications, between non-Hispanic White cancer COVID-19. <h3>Design, Setting, Participants</h3> This retrospective cohort study used data from Cancer Consortium registry March 17, 2020,...
PURPOSE There are limited data available on the real-world patterns of molecular testing in men with advanced prostate cancer. We thus sought to evaluate next-generation sequencing (NGS) United States, focused single versus serial NGS testing, different disease states (hormone-sensitive v castration-resistant, metastatic vs nonmetastatic), tissue plasma circulating tumor DNA (ctDNA) assays, and how often actionable were found each test. METHODS The Prostate Cancer Precision Medicine...
A series of tridentate cyclometalated platinum(II) complexes (C∧N*N)PtL (L = Cl or acetylide) featuring a fused five-six-membered metallacycle were synthesized. The structure the was confirmed by X-ray crystallography. In contrast to C∧N∧N platinum with five-five-membered metallacycle, coordination in C∧N*N is much closer square planar geometry. photophysical properties studied. geometrical change from led substantial improvement phosphorescence efficiency an acetylide ligand solution at...
A series of cyclometalating ligands, N-phenyl-N-(3-(pyridin-2-yl)phenyl)pyridin-2-amine (L1), N-(3-(1H-pyrazol-1-yl)phenyl)-N-phenylpyridin-2-amine (L2), N-phenyl-N-(3-(quinolin-2-yl)phenyl)pyridin-2-amine (L3), N-phenyl-N-(3-(pyridin-2-yl)phenyl)quinolin-2-amine (L4), N-(3-(isoquinolin-1-yl)phenyl)-N-phenylpyridin-2-amine (L5), and N-phenyl-N-(3-(pyridin-2-yl)phenyl)isoquinolin-1-amine (L6), were synthesized, which reacted with K(2)PtCl(4) in glacial acetic acid to produce N^C*N-coordinated...
Several immune checkpoint inhibitors (ICIs) are approved for the treatment of advanced urothelial carcinoma (UC). There limited biomarkers ICI-treated patients with UC. We investigated association between body composition and clinical outcomes in UC patients.We conducted a retrospective analysis 70 at Winship Cancer Institute from 2015 to 2020. Baseline computed tomography images within 2 months ICI initiation were collected mid-L3 muscle fat compartments (subcutaneous, intermuscular,...
The modified Glasgow prognostic score (mGPS), a clinical tool that incorporates albumin and C-reactive protein, has proven useful in the prognostication of multiple cancers. Several immune checkpoint inhibitors (ICIs) have been approved for treatment metastatic urothelial cell carcinoma (mUC), but biomarker is needed. We investigated impact mGPS on survival outcomes patients with mUC receiving ICIs.We retrospectively reviewed treated ICIs (programmed death protein 1 or programmed ligand...
Background The modified Glasgow Prognostic Score (mGPS) is a composite biomarker that uses albumin and C reactive protein (CRP). There are multiple immune checkpoint inhibitor (ICI)-based combinations approved for metastatic renal cell carcinoma (mRCC). We investigated the ability of mGPS to predict outcomes in patients with mRCC receiving ICI. Methods retrospectively reviewed treated ICI as monotherapy or combination at Winship Cancer Institute between 2015 2020. Overall survival (OS)...
Adrenocortical carcinoma (ACC) is a rare and heterogeneous malignancy with poor prognosis. We aimed to evaluate the feasibility of next-generation sequencing (NGS) testing circulating cell-free tumor DNA (ctDNA) in patients ACC, characterize genomic landscape alterations, identify potential clinically actionable mutations.Retrospective analysis data from 120 ACC who had ctDNA between 12/2016 10/2021 using Guardant360 (Guardant Health, CA) was performed. NGS interrogated single nucleotide...
The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether outcomes this patient population were associated geography. To quantify variation among patients cancer. This registry-based retrospective cohort study included historical diagnosis invasive malignant neoplasm and laboratory-confirmed SARS-CoV-2 infection between March November 2020. Data...
Biomarkers have the potential to guide treatment selection and clinical care in metastatic renal cell carcinoma (mRCC) an expanding landscape. We report baseline neutrophil-to-eosinophil ratios (NER) patients with mRCC treated immune checkpoint inhibitors (CPIs) their association outcomes.We conducted a retrospective review of CPIs at Winship Cancer Institute from 2015 2020 United States America (USA). Demographics, disease characteristics, laboratory data, including complete blood counts...
We developed a novel risk scoring system for urothelial cancer (UC) patients receiving immune checkpoint inhibitors (ICI).We conducted retrospective review of 67 UC treated with ICI at Winship Cancer Institute Emory University from 2015 to 2018. Using stepwise variable selection in Cox proportional hazard model and Sullivan's weighting schema, baseline platelet-to-lymphocyte ratio (PLR), presence liver metastasis, albumin, Eastern Cooperative Oncology Group performance status (ECOG PS) were...
Pembrolizumab has been approved by the US Food and Drug Administration for treatment of metastatic or unresectable solid tumors that are microsatellite instability-high (MSI-H) mismatch repair deficient. Blood-based circulating tumor DNA (ctDNA) assays have validated to identify with MSI-H status without need tissue biopsy. We report 2 patients castration-resistant prostate cancer (mCRPC) who had prior multiple lines therapy underwent ctDNA testing, which detected status. Both were treated...
The outcomes of metastatic hormone-sensitive prostate cancer (mHSPC) have significantly improved through treatment intensification, yet Black representation in those studies is suboptimal.A multi-institutional, retrospective analysis men with mHSPC was conducted, focusing on baseline demographics, patterns, genomic profiles, clinical including prostate-specific antigen response, time to castrate-resistant (CRPC), and subsequent treatments.A total 107 patients, median age 64 years, 62% de...
Advanced prostate cancer (aPC) in Black men was reported to present with aggressive features and be associated poor prognosis. Herein, we compared the cell-free DNA (cfDNA) genomic landscape of aPC vs White men. Patients (pts) from 6 academic institutions available cfDNA comprehensive profiling (CGP) were included. Association between mutated genes race evaluated using Barnard's test a Probabilistic Graphical Model (PGM) machine learning approach. Analysis included 743 pts (217 Black, 526...
Cyclometalating ligands 6-(1-phenylethyl)-2,2′-bipyridine (L4), 6-(1-phenylvinyl)-2,2′-bipyridine (L5), and 6-(prop-1-en-2-yl)-2,2′-bipyridine (L6) were synthesized by the Negishi coupling of 6-bromo-2,2′-bipyridine with corresponding organozinc reagents. The reaction L4 K2PtCl4 produced only cycloplatinated compound 4a via sp2 C–H bond activation. reactions L5 L6 exclusively compounds 5b 6a, respectively, vinylic DFT calculations performed on 12 possible cycloplatination products from...
A paraneoplastic syndrome can often present as the first manifestation of an underlying malignancy. We report a patient who presented with cholestatic jaundice from his newly diagnosed metastatic prostate cancer. He received initial treatment androgen deprivation therapy followed by six cycles docetaxel resulting in resolution process, normalization liver enzyme levels, and excellent biochemical radiographic response. To best our knowledge, this is reported case cancer phenomenon to be...
Mechanisms of dysfunctional T cell immunity in Hepatocellular Carcinoma(HCC) need to be well defined. B7 family molecules provide both co-stimulatory and co-inhibitory signals cells while tryptophan degrading enzymes like Indoleamine 2,3 dioxygenase(IDO) Tryptophan Dioxygenase(TDO) mediate tumor immune tolerance. It is necessary identify their situ correlative expression, which informs targets for combined immunotherapy approaches. We investigated molecules, IDO, TDO responsive effectors the...
Abstract Introduction COVID-19 particularly impacted patients with co-morbid conditions, including cancer. Patients melanoma have not been specifically studied in large numbers. Here, we sought to identify factors that associated severity among melanoma, assessing outcomes of on active targeted or immune therapy. Methods Using the and Cancer Consortium (CCC19) registry, identified 307 diagnosed COVID-19. We used multivariable models assess demographic, cancer-related, treatment-related a...
472 Background: The increasing use of IO agents in the treatment urothelial cancer has revealed irAEs during therapy. We investigated whether there is an association between treatment-related and CO pts treated with IO. Methods: performed a retrospective analysis 67 PD-1/PD-L1 inhibitors at Winship Cancer Institute from 2015-2018. Overall survival (OS) progression free (PFS) were calculated first dose to date death or hospice referral clinical radiographic progression, respectively....